Phenyl ureas of creatinine as mGluR5 antagonists. A structure-activity relationship study of fenobam analogues.

Fenobam (1) was developed by McNeil Laboratories as an anxiolytic agent with an unknown molecular target in the late 1970s. In a recent publication, it was revealed that fenobam is a non-competitive mGluR5 antagonist. Herein, we present the structure-activity relationship of fenobam and its analogues and similarities between the SAR of mGluR5 antagonism and the SAR of CNS properties originally reported by McNeil are discussed.

[1]  W. Spooren,et al.  Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. , 2000, The Journal of pharmacology and experimental therapeutics.

[2]  T. B. Johnson,et al.  RESEARCHES ON HYDANTOINS. XXXV. A NEW METHOD OF SYNTHESIZING GLYCOCYAMIDINE COMPOUNDS, AND THE CONVERSION OF GLYCOCYAMIDINE INTO ISOMERS OF CREATININE. , 1915 .

[3]  J. Pin,et al.  Pharmacology and functions of metabotropic glutamate receptors. , 1997, Annual review of pharmacology and toxicology.

[4]  Jesse Brodkin,et al.  Anxiolytic-like activity of the mGluR5 antagonist MPEP A comparison with diazepam and buspirone , 2002, Pharmacology Biochemistry and Behavior.

[5]  M. D. Armstrong.  The Preparation of N-Ethylglycocyamine. Double Salt Formation Between Guanidines and Amino Acids , 1956 .

[6]  J. Pecknold,et al.  Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. , 1982, Journal of clinical psychopharmacology.

[7]  R. Gereau,et al.  Metabotropic glutamate receptor involvement in models of acute and persistent pain: prospects for the development of novel analgesics. , 2002, Current drug targets. CNS and neurological disorders.

[8]  Jens-Uwe Peters,et al.  Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity , 2005, Journal of Pharmacology and Experimental Therapeutics.

[9]  V. Mutel.  Therapeutic potential of non-competitive, subtype-selective metabotropic glutamate receptor ligands , 2002 .

[10]  W. Wu,et al.  In vitro and in vivo metabolism of the antianxiolytic agent fenobam in the rat. , 1995, Journal of pharmaceutical sciences.

[11]  R. Duvoisin,et al.  The metabotropic glutamate receptors: Structure and functions , 1995, Neuropharmacology.

[12]  K. Bloch,et al.  Bate of formation and disappearance of body creatine in normal animals. , 1941 .

[13]  Fabrizio Gasparini,et al.  mGlu5 receptor antagonists: a novel class of anxiolytics? , 2004, Drug news & perspectives.

[14]  N. Schwartz,et al.  2-Pyrrolidinylideneureas, a new class of central nervous system agents. , 1978, Journal of medicinal chemistry.

[15]  F. Gasparini,et al.  Potential anxiolytic‐ and antidepressant‐like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist , 2001, British journal of pharmacology.

[16]  L. Blackshaw,et al.  Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist. , 2005, European journal of pharmacology.

[17]  Fabio Maria Sabbatini,et al.  Metabotropic glutamate receptors: potential therapeutic applications of recently disclosed new chemical entities , 2004 .

[18]  F. Conquet,et al.  Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice , 2001, Nature Neuroscience.